Molecular Evidence of High Proportion of Plasmodium vivax Malaria Infection in White Nile Area in Sudan
Plasmodium falciparum is a predominant malaria species that infects humans in the African continent. A recent WHO report estimated 95% and 5% of P. falciparum and P. vivax malaria cases, respectively, in Sudan. However many laboratory reports from different areas in Sudan indicated otherwise. In order to verify, we selected four hundred suspected malaria cases from Aljabalain area located in the White Nile state, central Sudan, and diagnosed them with quality insured microscopy and species-specific nested PCR. Our results indicated that the proportion of P. vivax infections among suspected malaria cases was high. We found that on average 20% and 36.5% of malaria infections in both study areas were caused by P. vivax using both microscopy and PCR, respectively. This change in pattern is likely due to the recent demographic changes and high rate of immigration from neighbouring countries in the recent years. This is the first extensive clinical study of its kind that shows rising trend in P. vivax malaria cases in White Nile area, Sudan.
Malaria is an infectious disease of humans and other animals caused by Plasmodium parasites . According to the latest WHO estimates, there were about 198 million cases of malaria in 2013 (with an uncertainty range of 124 million to 283 million) and an estimated 584 000 deaths (with an uncertainty range of 367 000 to 755 000) in the world . Malaria mortality rates have fallen by 47% globally since 2000 and by 54% in the WHO African Region .
Five species of plasmodia can infect humans. The vast majority of deaths in Sub-Saharan regions are caused by P. falciparum, while P. vivax, P. ovale, P. malariae, and P. knowlesi cause generally milder form of malaria which other than P. knowlesi is rarely fatal [1, 3].
P. vivax is responsible for most malaria cases in Asia and Latin America but it is almost absent from most of central Africa due to the absence of Duffy antigen, the receptor which P. vivax uses to invade human erythrocytes . In eastern and southern Africa, P. vivax represents around 10% to 40% of malaria cases but <1% of cases in western and central Africa [4, 5].
In Sudan until recently the majority of malaria cases were caused by P. falciparum. P. vivax is relatively rare; 95% of cases are caused by P. falciparum and the other 5% are caused by P. vivax . However, in recent years many clinicians observed recurrent relapses of malaria infections in different areas in Sudan suggesting perhaps a higher than expected transmission of non-falciparum malaria parasites (most likely P. vivax since it is the second most important malaria parasite species in Sudan). The objective of this study was to document the suggested rise in the proportion of P. vivax infections among suspected malaria cases in White Nile state in Sudan.
2. Materials and Methods
2.1. Ethical Considerations
The study was approved by the ethical committee of the Institute of endemic diseases, University of Khartoum. Informed consent was obtained from each patient before participation in the study.
2.2. Study Area and Sample Collection
This study was a cross-sectional study carried out in the White Nile area which is one of the central Sudan states, Figure 1. It lies between latitudes 33 and 30-31 north and longitude 13 and 30–12 east, occupying an area of around 675000 km2, with population of 1.675 million. The study was conducted in Aljabalain area, 80 km south of Rabak town, the capital of White Nile state. The area is considered mesoendemic for malaria; transmission follows mainly the rainy season (July to October). Four hundred suspected malaria cases based on patient’s symptoms (fever, headache, sweating, nausea, and vomiting) and signs (pyrexia, pallor) were chosen randomly from Aljabalain hospital and Aljabalain military hospital aged >1 year old regardless of gender. Samples were collected during the rainy season (July–September) in 2012. All suspected malaria cases were treated with a standard regimen (artemisinin based combination therapy) by the local malaria control program according to the Sudanese Malaria Treatment Guidelines in Sudan National Malaria Control Program (NMCP), and the National Protocol for Treatment of Malaria (Federal Ministry of Health, Khartoum, Sudan, 2013, unpublished).
2.3. Diagnosis of Malaria
Two and a half mL of venous blood was obtained from each patient. Malaria was diagnosed using blood film microscopy and confirmed with PCR. Both thick and thin blood films were used, fields were read at least twice, and the procedure was followed according to quality control guidelines of WHO. PCR was done for both P. falciparum and P. vivax. The PCR was performed at the Institute of Endemic Diseases, University of Khartoum, with quality control in place (both positive and negative control were used). Parasite genomic DNA was extracted from whole blood samples using Chelex method. A fragment of the plasmodial 18S rRNA gene was amplified by PCR and species identification was performed with species-specific oligoprobes using the following primers: for P. falciparum, rPLU5: 5′ CTTGTTGTTGCCTTAAACTTC-3′, rPLU6: 5′-TTAAAATTGTTGCATTAAAACG-3′; for P. vivax, rVIV1: 5′-CGCTTCTAGCTTAACCACATAACTGATAC-3′, rVIV2: 5′-ACTTCCAAGCCGAAG CAAAGA AAG TCC TTA-3′, as described previously .
2.4. Statistical Analysis
Data were analyzed using SPSS (statistical package for the social sciences) version twentieth software.
In our study, both males and females are affected by malaria; however more females were represented in Aljabalain hospital (64.4%) and more males were represented from Aljabalain military hospital (64%). The average haemoglobin level in all patients from the two study sites was 11.9 g/dL. The prevalence of anaemia among malaria patients was high, more than two-thirds in both study sites. The majority of malaria cases (more than 90%) had low parasite level (≤500 parasite/μL of blood), Table 1.
In both study sites, the proportion of P. vivax infections among suspected malaria cases was high. Microscopy results showed that 30 (15%) and 50 (25%) of malaria infections in Aljabalain hospital and Aljabalain military hospital were caused by P. vivax. The results were even higher with PCR (Figure 2); 66 (33%) and 80 (40%) of samples from Aljabalain hospital and Aljabalain military hospital were positive for P. vivax, respectively. Mixed infections (P. falciparum + P. vivax) were detected in 2.25% of samples in average from both study areas, Table 2.
This study was carried out in an area characterized by seasonal and unstable malaria transmission. The most remarkable result in this study was the unexpected high proportion (about 40% by PCR) of P. vivax infections among suspected malaria cases, eight times more than that previously reported in Sudan . This change in pattern is most likely due to the recent varied composition of the community resulting from several migrations of people from several Asian and African countries to work at petroleum and new sugar companies in White Nile area especially from Ethiopia where high prevalence of P. vivax infection (31%) among malaria cases was found .
Another suggested explanation for the emergence of P. vivax is parasite’s development of alternative mechanisms to invade human erythrocytes other than the Duffy antigen. This is a plausible explanation since P. vivax infection of Duffy negative genotype was reported previously in many African countries [8–16]. This is the first study of its kind to document the significant rise in malaria P. vivax transmission in Sudan. And it has important health policy implications since P. vivax infection requires eradication of liver stages with primaquine due to presence of dormant hypnozoites within hepatocytes [17, 18]. Recent data showed that P. vivax infection is becoming more severe especially in children, and further studies are required to understand the exact causes of this pattern .
The sampled population (four hundred cases) of this study was selected based on their highly suspected symptoms of malaria and positive blood film microscopy done in hospitals’ laboratories. Blood films were later proved only 50% positive in more quality insured settings. This obvious result of malaria overdiagnosis by a factor of two is probably due to lack of training in general hospitals, low quality control microscopy, and high work load. The same result was previously found in Tanzania where malaria was overdiagnosed by a factor of five [20, 21].
PCR diagnosis for malaria is accurate especially for differentiating between plasmodia species, but it is expensive and needs well-trained personnel. In this study quality control microscopy allowed for 20% of Plasmodium vivax diagnosis, while by PCR it was 38.7%. This may be due to difficulty in differentiation between species based on a single ring form especially for untrained personnel. In this study more than 90% of slides had low parasite density (≤500 parasite/μL); this also makes differentiation between plasmodia species very difficult.
Our study confirmed the observed high percentage of P. vivax infections in White Nile area, central Sudan. This result has important implications for the malaria control and necessitates modification of current guidelines for the treatment of malaria in Sudan.
|BFFM:||Blood film for malaria|
|PCR:||Polymerase chain reaction|
All authors declare no competing interests.
Muzamil Mahdi Abdel Hamid, Makarim M. Adam Suliman, and Bushra M. Hamad made substantial contributions to the conception and the design of the study. Musab M. Ali Albasheer did the lab work. Analysis and interpretation of data was done by Muzamil Mahdi Abdel Hamid, Makarim M. Adam Suliman, and Bushra M. Hamad. Muzamil Mahdi Abdel Hamid, Maha Elobied, and Mutaz Amin Mustafa revised the manuscript and Mutaz Amin Mustafa wrote it. Muzamil Mahdi Abdel Hamid gave final approval of the version to be published; all authors read and approved the final manuscript.
The authors send their gratitude to the patients and families who participated in this study. This study was funded by TWAS research Grant agreement no. 13-145 RG/BIO/AF/AC_G.
Centers for Disease Control and Prevention, “Malaria Worldwide,” September 2015 http://www.cdc.gov/malaria/malaria_worldwide/index.htmlView at: Google Scholar
WHO, “Malaria,” 2015, http://www.who.int/mediacentre/factsheets/fs094/en/View at: Google Scholar
K. Mendis, B. J. Sina, P. Marchesini, and R. Carter, “The neglected burden of Plasmodium vivax malaria,” The American Journal of Tropical Medicine and Hygiene, vol. 64, no. 1-2, supplement, pp. 97–106, 2001.View at: Google Scholar
L. Golassa, F. N. Baliraine, N. Enweji, B. Erko, G. Swedberg, and A. Aseffa, “Microscopic and molecular evidence of the presence of asymptomatic Plasmodium falciparum and Plasmodium vivax infections in an area with low, seasonal and unstable malaria transmission in Ethiopia,” BMC Infectious Diseases, vol. 15, no. 1, article 310, 2015.View at: Publisher Site | Google Scholar
G. Snounou and B. Singh, “Nested PCR analysis of Plasmodium parasites,” Methods in molecular medicine, vol. 72, pp. 189–203, 2002.View at: Google Scholar
K. Sondén, E. Castro, L. Trönnberg, C. Stenström, A. Tegnell, and A. Färnert, “High incidence of Plasmodium vivax malaria in newly arrived Eritrean refugees in Sweden since may 2014,” Eurosurveillance, vol. 19, no. 35, pp. 1–4, 2014.View at: Google Scholar
H. M. Mathews and J. C. Armstrong, “Duffy blood types and vivax malaria in Ethiopia,” American Journal of Tropical Medicine and Hygiene, vol. 30, no. 2, pp. 299–303, 1981.View at: Google Scholar
J. R. Ryan, J. A. Stoute, J. Amon et al., “Evidence for transmission of Plasmodium vivax among a Duffy antigen negative population in Western Kenya,” American Journal of Tropical Medicine and Hygiene, vol. 75, no. 4, pp. 575–581, 2006.View at: Google Scholar